Deals Of The Week: AMAG/Allos, Pfizer/Icagen, Allergan/Vicept, BMS/Amira
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
The combination of Medco’s market-leading specialty drug pharmacy unit, Accredo, with Express Scripts’ specialty businesses would create a dominant player controlling more than 52% of the market, based on research by Pembroke Consulting.
The proposed merger of two of the three major pharmacy benefit managers may have tough time clearing FTC; the agency has rejected other deals that would have left only two dominant players in a sector.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.